Manufacturer record
Bactolac Formulations Pvt. Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
5 batches manufactured by Bactolac Formulations Pvt. Ltd (Telangana) were declared Not of Standard Quality between January 2026 and May 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
5 records linked to Bactolac Formulations Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Clopidogrel Tablets IP | BCGT25020Mfg 2025-06 · Exp 2027-05 | Content & DissolutionDissolution | DTL, Chennai-06State lab | May 2026 |
| Clopidogrel Tablets IP | BCGT25021Mfg 2025-06 · Exp 2027-05 | DescriptionDescription | DTL, Chennai-06State lab | Feb 2026 |
| Clopidogrel Tablets IP | BCGT25042Mfg 2025-07 · Exp 2027-06 | DescriptionDescription | Drugs Testing Laboratory, Chennai-06State lab | Jan 2026 |
| Clopidogrel Tablets IP | BCGT25048Mfg 2025-07 · Exp 2027-06 | DescriptionDescription | Drugs Testing Laboratory, Chennai-06State lab | Jan 2026 |
| Clopidogrel Tablets IP | BCGT25049Mfg 2025-07 · Exp 2027-06 | DescriptionDescription | Drugs Testing Laboratory, Chennai-06State lab | Jan 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.